PT - JOURNAL ARTICLE AU - Xiaoyan Liu AU - Zhe Li AU - Shuai Liu AU - Zhanghua Chen AU - Jing Sun AU - Zhiyao Zhao AU - Yi-you Huang AU - Qingling Zhang AU - Jun Wang AU - Yinyi Shi AU - Yanhui Xu AU - Huifang Xian AU - Rongli Fang AU - Fan Bai AU - Changxing Ou AU - Bei Xiong AU - Andrew M Lew AU - Jun Cui AU - Hui Huang AU - Jincun Zhao AU - Xuechuan Hong AU - Yuxia Zhang AU - Fuling Zhou AU - Hai-Bin Luo TI - Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction AID - 10.1101/2020.02.27.20027557 DP - 2020 Jan 01 TA - medRxiv PG - 2020.02.27.20027557 4099 - http://medrxiv.org/content/early/2020/02/29/2020.02.27.20027557.short 4100 - http://medrxiv.org/content/early/2020/02/29/2020.02.27.20027557.full AB - The human coronavirus HCoV-19 infection can cause acute respiratory distress syndrome (ARDS), hypercoagulability, hypertension, extrapulmonary multiorgan dysfunction. Effective antiviral and anti-coagulation agents with safe clinical profiles are urgently needed to improve the overall prognosis. We screened an FDA approved drug library and found that an anticoagulant agent dipyridamole (DIP) suppressed HCoV-19 replication at an EC50 of 100 nM in vitro. It also elicited potent type I interferon responses and ameliorated lung pathology in a viral pneumonia model. In analysis of twelve HCoV-19 infected patients with prophylactic anti-coagulation therapy, we found that DIP supplementation was associated with significantly increased platelet and lymphocyte counts and decreased D-dimer levels in comparison to control patients. Two weeks after initiation of DIP treatment, 3 of the 6 severe cases (60%) and all 4 of the mild cases (100%) were discharged from the hospital. One critically ill patient with extremely high levels of D-dimer and lymphopenia at the time of receiving DIP passed away. All other patients were in clinical remission. In summary, HCoV-19 infected patients could potentially benefit from DIP adjunctive therapy by reducing viral replication, suppressing hypercoagulability and enhancing immune recovery. Larger scale clinical trials of DIP are needed to validate these therapeutic effects.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000030055Funding StatementNational Key R&D Program of China (2017YFB0202600), National Natural Science Foundation of China (91742109, 8152204, 31770978, 81773674, and 21877134), Taikang Insurance Group Co., Ltd and Beijing Taikang Yicai Foundation, and philanthropy donation from individuals. The funders had no roles in the design and execution of the study.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.